Vaccine-preventable HPV burden and cervical abnormalities in women during 2022–2024 Octobre Rose campaigns in Libreville Authors: Alfred K. F. Mabika-Obanda, Nathalie Ambounda Ledaga, Krystina Ngou Milama, Vénusia Zang Obame, Amel Kevin Alame-Emane, Adama Sanon, Corneille Ndong-Ella, Hugues Loemba, Laurent Bélec, Jean-Pierre Ngou Mve Ngou, Paulin N. Essone, Armel Mintsa-Ndong, Ralph-Sydney Mboumba Bouassa, Joël Fleury Djoba Siawaya Published: 2025 ABSTRACT Cervical cancer is a leading cause of mortality in sub-Saharan Africa, largely driven by persistent carcinogenic human papillomavirus (HPV) infection. We conducted a 3-year cross-sectional study of 1,524 women participating in the national “Octobre Rose” campaigns in Libreville, Gabon. Cervical samples were assessed by visual inspection with acetic acid/Lugol iodine (VIA/VILI) and HPV genotyping using BioPerfectus Multiplex Real-Time PCR assay. Overall HPV prevalence was 21.0%, including 18.5% carcinogenic types and 11.0% covered by the nonavalent vaccine. HPV-35 was dominant, while Gardasil-9-targeted genotypes accounted for 63% of carcinogenic infections and the largest attributable fraction of VIA/VILI-detected abnormalities, particularly HPV-16 and HPV-45. HIV and high lifetime sexual exposure were independent predictors of carcinogenic HPV. These findings reveal a substantial burden of vaccine-preventable HPV in Gabon and underscore the high potential impact of Gardasil-9 implementation, while reinforcing the need for continued HPV-based screening to mitigate residual risk of non-vaccine types such as HPV-35. Introduction Cervical cancer, often referred to as the “silent killer” for its protracted, asymptomatic course, remains the second most frequently diagnosed female cancer and the second leading cause of cancer death in women in sub-Saharan Africa (SSA), accounting for an estimated 125,699 new cases and 80,614 deaths in 20231,2. In Middle Africa, where Gabon is located, cervical cancer is the second most common cancer in women (16,268) and the leading cause of cancer-related deaths (11,293), surpassing breast cancer (9142)2. Cervical cancer is primarily driven by persistent infection with carcinogenic human papillomavirus (HPV) genotypes, particularly HPV-16, −18, −31, −33, −35, −39, −45, −51, −52, −56, −58, −59, and −683–5. While the distribution of HPV genotypes shows regional heterogeneity, HPV-16, HPV-35, HPV-52, and HPV-58 are consistently reported among the most prevalent types in Central Africa5–18. The world health organization (WHO) advocates a triple prevention strategy, relying primarily on HPV-based screening, visual triage with acetic acid (VIA), Lugol iodine (VILI), or liquid-based cytology, and prophylactic vaccination with multivalent HPV vaccines such as the nonavalent Gardasil-9®, which targets seven carcinogenic HPV types (HPV-16, −18, −31, −33, −45, −52, −58) responsible for more than 90% of cervical cancers worldwide1,3,5. While this approach has markedly reduced incidence and mortality in high-income countries, limited access to these interventions in low- and middle-income countries sustains the high disease burden1. The republic of Gabon, located on the west coast of Central Africa, has a population of approximately 2.54 million, including more than 520,000 women of childbearing age (15–44 years) who are at risk of carcinogenic HPV infection19,20. Libreville, the capital, has hosted the annual “Octobre Rose” cervical cancer screening campaign since 2013, offering HPV testing and VIA/VILI-based screening alongside public awareness and prevention education10. However, a decade on, national cervical cancer incidence and mortality remain high (236 new cases and 118 deaths in 2023)20, and HPV vaccines are absent from the national immunisation schedule21 despite WHO’s recent endorsement of a single-dose regimen to boost coverage22. Robust, population-based genotype surveillance is essential to generate national-level HPV prevalence data that complement WHO regional estimates, thereby providing evidence to guide the vaccination strategy in Gabon, monitor shifts in HPV ecology, and refine screening and triage algorithms for cervical cancer prevention. Most Gabonese studies have focused on women referred for cervical cancer screening because of gynecological symptoms or those with confirmed precancerous lesions, reporting a wide range of carcinogenic HPV prevalence (24.8–94.6%) and predominance of genotypes targeted by the nonavalent vaccine6,10–13,16,18. However, data derived from the general population remain scarce. Here, we investigate the distribution of carcinogenic HPV genotypes, population attributable fraction (PAF) of VIA/VILI-based cytological outcomes, and associated risk factors among 1524 adult women participating in the 2022-2024 Octobre Rose screening campaigns in Libreville, Gabon. This outreach-based cohort study provides the most comprehensive description to date of vaccine-preventable carcinogenic HPV burden and related cervical abnormalities in the country. We establish a representative baseline prevalence of genital HPV infection (21.0%) and carcinogenic types (18.5%), consistent with WHO regional estimates for sub-Saharan Africa3. Our analysis shows that nearly 90% of all infections involve at least one carcinogenic HPV type, which collectively account for about 18% of VIA/VILI-detected abnormalities. Nonavalent vaccine genotypes represent 63% of carcinogenic infections, and up to 68% of VIA/VILI-positive women with high-risk infections carry a vaccine-preventable type. The greatest attributable burden is observed for nonavalent vaccine-targeted types (PAF: 14.1%), particularly HPV-16 (PAF: 5.3%) and HPV-45 (PAF: 3.3%), consistent with their well-established oncogenic dominance5. HPV-35 emerges as the most common non-vaccine carcinogenic type, yet its inclusion in future formulations could expand protection to roughly 76% of infections observed herein. Together, these findings define a critical baseline for monitoring vaccine impact and guiding integrated HPV vaccination and screening strategies in Gabon. Results Study population characteristics As shown in Fig. 1, 1579 adult women (≥18 years) residing in Libreville were recruited during the 2022, 2023, and 2024 “Octobre Rose” campaigns. All underwent medical interviews, genital sampling, and cytological examination. Forty-nine women were excluded due to uninterpretable HPV genotyping results, and six were excluded for history of hysterectomy, yielding a final study population of 1524 women (median age 38 years; IQR 29–48) with valid HPV genotypic data.Fig. 1Flowchart of participant recruitment and inclusion in the study population.This figure illustrates the recruitment and inclusion process of women enrolled through the Octobre Rose 2022-2024 cervical cancer screening campaigns in Libreville. Numbers of exclusions and the final cohort size (n = 1524) are shown, with annual enrolments detailed. Flowchart of participant recruitment and inclusion in the study population. This figure illustrates the recruitment and inclusion process of women enrolled through the Octobre Rose 2022-2024 cervical cancer screening campaigns in Libreville. Numbers of exclusions and the final cohort size (n = 1524) are shown, with annual enrolments detailed. Participant characteristics are summarised in Table 1. Most participants were younger than 50 years, including 443 (29.07%) aged 30–39 years, 394 (25.85%) aged 18–29 years, and 343 (22.51%) aged 40–49 years. A minority of women (n = 225, 14.76%) were aged 50–59 years, and 119 (7.81%) were aged 60 years or older. Nearly half of participants were single (n = 659, 43.24%), 301 (19.75%) were married, and 405 (26.57%) were in cohabitation unions, while 65 (4.27%) were widowed. Regarding education, 984 (64.56%) participants had at least completed high school, including 485 (31.82%) with a university degree. Elementary schooling was the highest level attained by 152 (9.97%) women, while 75 (4.92%) had never attended school. Employment was reported by 711 (46.65%) participants, either salaried (n = 399; 26.18%) or with no regular or informal job (n = 312; 20.47%), whereas 495 (32.48%) were unemployed, 138 (9.06%) were students, and 42 (2.76%) were retired. Most women (n = 967; 63.45%) reported fewer than ten lifetime sexual partners, while 196 (12.86%) reported more than 10. Gravidity was common, as 867 (56.89%) women have had up to five pregnancies, 308 (20.21%) up to nine, and 91 (5.97%) more than ten, whereas a minority of participants (n = 173, 11.35%) were nulligravida. Parity was similarly high, as 984 (64.57%) women have had up to five births, 154 (10.10%) up to nine, and 21 (1.38%) more than ten; only a minority of women (n = 280, 18.37%) were nulliparous. Menopause was reported by 335 (21.98%) participants, and 90 (5.91%) women were living with HIV.Table 1Characteristics of the Gabonese women included in the study (n = 1524)Total study participants (n = 1524)Characteristicsn (%) [95% CI]aAge (years) [n (%) CI]Median age (Interquartile range) years38 (29–48) [18–29]394 (25.85) [23.65–28.05] [30–39]443 (29.07) [26.79–31.35] [40–49]343 (22.51) [20.41–24.60] [50–59]225 (14.76) [12.98–16.54] ≥60119 (7.81) [6.46–9.16]Marital status [n (%) CI] Single659 (43.24) [40.75–45.73] Married301 (19.75) [17.75–21.75] Cohabitation union405 (26.57) [24.36–28.79] Widowed65 (4.27) [3.25–5.28] Missing datab94 (6.17) [4.96–7.38]Highest education level [n (%) CI] Never schooled75 (4.92) [3.84–6.01] Elementary school152 (9.97) [8.47–11.48] High school499 (32.74) [30.39–35.10] University485 (31.82) [29.49–34.16] Missing data313 (20.54) [18.51–22.57]Employment status [n (%) CI] Employee with a regular monthly salary399 (26.18) [23.97–28.39] No regular or informal job312 (20.47) [18.45–22.50] Student138 (9.06) [7.61–10.50] Without paid employment495 (32.48) [30.13–34.83] Retired42 (2.76) [1.93–3.58] Missing data138 (9.06) [7.61–10.50]Lowest number of lifetime sexual partners [n (%) CI] 1450 (29.53) [27.29–31.87] 2–5517 (33.92) [31.55–36.30] 6–9166 (10.89) [9.33–12.46] ≥ 10196 (12.86) [11.18–14.54] Missing data195 (12.80) [11.12–14.47]Gravidity [n (%) CI] 0173 (11.35) [9.76–12.94] 1–5867 (56.89) [54.40–59.38] 6–9308 (20.21) [18.19–22.23] ≥ 1091 (5.97) [4.78–7.16] Missing data85 (5.58) [4.43–6.73]Parity [n (%) CI] 0280 (18.37) [16.43–20.32] 1–5984 (64.57) [62.13–66.93] 6–9154 (10.10) [8.59–11.62] ≥ 1021 (1.38) [0.79–1.96] Missing data85 (5.58) [4.43–6.73]Menopause [n (%) CI]335 (21.98) [19.90–24.06]HIV status [n (%) CI]90 (5.91) [4.72–7.09]95% CI 95% confidence interval, HIV Human immunodeficiency virus, n Number (size of study group).aThe frequency of each variable is presented with their confidence interval in brackets.bMissing data stands for participants for whom we did not have the corresponding information. Table 1Characteristics of the Gabonese women included in the study (n = 1524)Total study participants (n = 1524)Characteristicsn (%) [95% CI]aAge (years) [n (%) CI]Median age (Interquartile range) years38 (29–48) [18–29]394 (25.85) [23.65–28.05] [30–39]443 (29.07) [26.79–31.35] [40–49]343 (22.51) [20.41–24.60] [50–59]225 (14.76) [12.98–16.54] ≥60119 (7.81) [6.46–9.16]Marital status [n (%) CI] Single659 (43.24) [40.75–45.73] Married301 (19.75) [17.75–21.75] Cohabitation union405 (26.57) [24.36–28.79] Widowed65 (4.27) [3.25–5.28] Missing datab94 (6.17) [4.96–7.38]Highest education level [n (%) CI] Never schooled75 (4.92) [3.84–6.01] Elementary school152 (9.97) [8.47–11.48] High school499 (32.74) [30.39–35.10] University485 (31.82) [29.49–34.16] Missing data313 (20.54) [18.51–22.57]Employment status [n (%) CI] Employee with a regular monthly salary399 (26.18) [23.97–28.39] No regular or informal job312 (20.47) [18.45–22.50] Student138 (9.06) [7.61–10.50] Without paid employment495 (32.48) [30.13–34.83] Retired42 (2.76) [1.93–3.58] Missing data138 (9.06) [7.61–10.50]Lowest number of lifetime sexual partners [n (%) CI] 1450 (29.53) [27.29–31.87] 2–5517 (33.92) [31.55–36.30] 6–9166 (10.89) [9.33–12.46] ≥ 10196 (12.86) [11.18–14.54] Missing data195 (12.80) [11.12–14.47]Gravidity [n (%) CI] 0173 (11.35) [9.76–12.94] 1–5867 (56.89) [54.40–59.38] 6–9308 (20.21) [18.19–22.23] ≥ 1091 (5.97) [4.78–7.16] Missing data85 (5.58) [4.43–6.73]Parity [n (%) CI] 0280 (18.37) [16.43–20.32] 1–5984 (64.57) [62.13–66.93] 6–9154 (10.10) [8.59–11.62] ≥ 1021 (1.38) [0.79–1.96] Missing data85 (5.58) [4.43–6.73]Menopause [n (%) CI]335 (21.98) [19.90–24.06]HIV status [n (%) CI]90 (5.91) [4.72–7.09]95% CI 95% confidence interval, HIV Human immunodeficiency virus, n Number (size of study group).aThe frequency of each variable is presented with their confidence interval in brackets.bMissing data stands for participants for whom we did not have the corresponding information. Characteristics of the Gabonese women included in the study (n = 1524) 95% CI 95% confidence interval, HIV Human immunodeficiency virus, n Number (size of study group). aThe frequency of each variable is presented with their confidence interval in brackets. bMissing data stands for participants for whom we did not have the corresponding information. Prevalence and distribution of HPV genotypes Genital HPV outcomes are summarised in Table 2 and Fig. 2A. Overall HPV prevalence was 21.0% (n = 320), with carcinogenic genotypes detected in 18.46% (n = 284) of participants, accounting for 88.75% (284/320) of all HPV-positive women. At least one of the seven carcinogenic HPV types targeted by the nonavalent vaccine was identified in 11.0% (n = 179) of participants overall, representing 63.03% (179/284) of carcinogenic HPV-positive cases. More specifically, 42.95% (122/284) of carcinogenic infections were exclusively attributable to nonavalent vaccine-targeted genotypes, 34.15% (97/284) involved only non-vaccine carcinogenic types, and 15.84% (45/284) represented concurrent infections combining both vaccine and non-vaccine carcinogenic genotypes. Non-vaccine carcinogenic HPV types were detected in 9.91% (n = 151) of women, corresponding to 53.16% of all carcinogenic infections. Multiple carcinogenic HPV infections occurred in 5.58% (n = 85) of participants, most of which involved vaccine-targeted types (Table 2). The most frequent carcinogenic genotype was the non-vaccine HPV-35 (3.61%; n = 55), followed by HPV-52 (3.14%; n = 48), HPV-56 (2.75%; n = 42), HPV-16 (2.55%; n = 39), and HPV-58 (2.03%; n = 31). Possibly carcinogenic and non-oncogenic types were less frequent, with HPV-81 (1.96%; n = 30) and HPV-53 (1.57%; n = 24) being the most common. No significant variation in genotype distribution was observed across age groups (Fig. 2A).Fig. 2Distribution of Human Papillomavirus (HPV) genotypes by carcinogenic risk and VIA/VILI status.The graph shows the distribution of HPV genotypes in (A): overall study population (n = 1524) and (B): subgroup of women with VIA/VILI-positive abnormal cytology (n = 128). Black bars correspond to carcinogenic HPV genotypes, white bars represent non-oncogenic (NO) HPV genotypes, and the bars containing diagonals pointing downwards correspond to possibly carcinogenic (PC) HPV genotypes. Genotypes with an asterisk correspond to HPV genotypes targeted by the nonavalent vaccine.Table 2Genital HPV outcomes among women included in the study (n = 1524)Total study participants (n = 1524) n (%) [95% CI]aHPV DNA detection and genotypes [n (%) CI]Any genotype of HPV320 (21.00) [18.95–23.04]Multiple genotypes of HPV129 (8.46) [7.07–9.86]Carcinogenic HPV genotypes284 (18.64) [16.68–20.59]Multiple genotypes of carcinogenic HPV85 (5.58) [4.43–6.73]Any nonavalent vaccine-targeted HPVb186 (12.20) [10.56–13.85]Multiple nonavalent vaccine-targeted HPV36 (2.36) [1.60–3.12]Nonavalent vaccine-targeted carcinogenic HPV179 (11.75) [10.13–13.36]Multiple nonavalent vaccine carcinogenic HPV31 (2.03) [1.33–2.74]Non-vaccine carcinogenic HPVc151 (9.91) [8.41–11.41]Multiple non-vaccine carcinogenic HPV21 (1.37) [0.79–1.96]95% CI 95% confidence interval, HPV Human Papillomavirus, n Number (size of study group).aThe frequency of each variable is presented with their confidence interval in brackets.bThe nonavalent vaccine is effective against HPV genotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58.cThe non-vaccine carcinogenic HPV genotypes 35, 39, 51, 56, 59, 68. Distribution of Human Papillomavirus (HPV) genotypes by carcinogenic risk and VIA/VILI status. The graph shows the distribution of HPV genotypes in (A): overall study population (n = 1524) and (B): subgroup of women with VIA/VILI-positive abnormal cytology (n = 128). Black bars correspond to carcinogenic HPV genotypes, white bars represent non-oncogenic (NO) HPV genotypes, and the bars containing diagonals pointing downwards correspond to possibly carcinogenic (PC) HPV genotypes. Genotypes with an asterisk correspond to HPV genotypes targeted by the nonavalent vaccine. Table 2Genital HPV outcomes among women included in the study (n = 1524)Total study participants (n = 1524) n (%) [95% CI]aHPV DNA detection and genotypes [n (%) CI]Any genotype of HPV320 (21.00) [18.95–23.04]Multiple genotypes of HPV129 (8.46) [7.07–9.86]Carcinogenic HPV genotypes284 (18.64) [16.68–20.59]Multiple genotypes of carcinogenic HPV85 (5.58) [4.43–6.73]Any nonavalent vaccine-targeted HPVb186 (12.20) [10.56–13.85]Multiple nonavalent vaccine-targeted HPV36 (2.36) [1.60–3.12]Nonavalent vaccine-targeted carcinogenic HPV179 (11.75) [10.13–13.36]Multiple nonavalent vaccine carcinogenic HPV31 (2.03) [1.33–2.74]Non-vaccine carcinogenic HPVc151 (9.91) [8.41–11.41]Multiple non-vaccine carcinogenic HPV21 (1.37) [0.79–1.96]95% CI 95% confidence interval, HPV Human Papillomavirus, n Number (size of study group).aThe frequency of each variable is presented with their confidence interval in brackets.bThe nonavalent vaccine is effective against HPV genotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58.cThe non-vaccine carcinogenic HPV genotypes 35, 39, 51, 56, 59, 68. Genital HPV outcomes among women included in the study (n = 1524) 95% CI 95% confidence interval, HPV Human Papillomavirus, n Number (size of study group). aThe frequency of each variable is presented with their confidence interval in brackets. bThe nonavalent vaccine is effective against HPV genotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58. cThe non-vaccine carcinogenic HPV genotypes 35, 39, 51, 56, 59, 68. Sociodemographic and clinical determinants of genital HPV infection To identify factors associated with genital HPV outcomes, sociodemographic and clinical variables were assessed using univariate and multivariate logistic regression (Table 3). Three determinants were consistently associated with increased risk of HPV outcomes, such as reporting more than ten lifetime sexual partners, having cervical abnormalities on VIA/VILI screening, and living with HIV. Women with more than ten partners had the highest likelihood of HPV infection (aOR: 4.29, 95% CI: 2.00–9.20; P < 0.001), carcinogenic HPV (aOR: 3.22, 95% CI: 1.46–7.08; P < 0.01), and nonavalent vaccine-targeted carcinogenic HPV (aOR: 2.95, 95% CI: 1.40–6.24; P < 0.01). VIA/VILI-detected cervical abnormalities were similarly associated with HPV (aOR: 2.95, 95% CI: 1.65–5.28; P < 0.001), carcinogenic HPV (aOR: 2.92, 95% CI: 1.56–5.46; P < 0.001), and vaccine-targeted carcinogenic HPV (aOR: 2.41, 95% CI: 1.19–4.88; P = 0.014). HIV-positive women were at increased risk of HPV (aOR: 3.89, 95% CI: 1.83–8.24; P < 0.001), carcinogenic HPV (aOR: 3.18, 95% CI: 1.48–6.81; P < 0.01), vaccine-targeted carcinogenic HPV (aOR: 2.59, 95% CI: 1.11–6.07; P = 0.028), and non-vaccine carcinogenic HPV (aOR: 2.95, 95% CI: 1.16–7.50; P = 0.023). Reporting up to nine partners was also associated with non-vaccine carcinogenic HPV infection (aOR: 2.43, 95% CI: 1.02–5.74; P = 0.044).Table 3Logistic regression analyses of risk factors of HPV outcomes in Gabonese women (n = 1524) living in Libreville during 2022-2024HPVAny carcinogenic HPVNonavalent carcinogenic HPVdNon-vaccine carcinogenic HPVecOR [95% CI]PaaOR [95% CI]PcOR [95% CI]PaOR [95% CI]PcOR [95% CI]PaOR [95% CI]PcOR [95% CI]PaOR [95% CI]PAge<30REFcREFREFREFREFREFREFREFREFREFREFREFREFREFREF[30–39]0.77 [0.42–10.43]0.414NAbNA0.69 [0.36–1.32]0.263NANA0.94 [0.43–2.04]0.875NANA0.40 [0.17–0.93]0.0330.76 [0.35–1.66]0.493[40–49]0.96 [0.53–1.73]0.884NANA0.84 [0.45–1.56]0.581NANA0.99 [0.46–2.14]0.987NANA0.54 [0.25–1.17]0.118NANA[50–59]0.93 [0.48–1.81]0.825NANA0.89 [0.45–1.78]0.741NANA10.17 [0.51–2.69]0.704NANA0.55 [0.23–1.34]0.191NANA≥600.58 [0.23–1.44]0.239NANA0.64 [0.25–1.60]0.339NANA0.87 [0.29–2.58]0.803NANA0.51 [0.16–1.59]0.245NANAOccupation statusEmployeeREFREFREFREFREFREFREFREFREFREFREFREFREFREFREFStudent2.90 [0.98–8.58]0.0501.85 [0.58–5.90]0.2973.74 [1.25–11.21]0.0182.31 [0.73–7.32]0.1531.07 [0.23–5.02]0.929NANA4.31 [1.22–15.25]0.0232.79 [0.81–9.65]0.105Retired1.42 [0.85–2.37]0.181NANA1.56 [0.48–5.05]0.457NANA3.22 [0.93–11.08]0.064NANA1.44 [0.30–6.87]0.651NANAHighest education levelNever schooled0.97 [0.37–2.57]0.953NANA0.98 [0.35–2.74]0.975NANA1.17 [0.35–3.88]0.798NANA1.05 [0.29–3.87]0.937NANAHigh school1.18 [0.60–2.29]0.633NANA1.25 [0.62–2.51]0.531NANA1.34 [0.58–3.12]0.491NANA1.12 [.45–2.77]0.806NANAUniversity0.72 [0.37–1.40]0.331NANA0.70 [0.35–1.43]0.333NANA0.75 [0.32–1.78]0.514NANA0.78 [0.31–1.95]0.596NANAMarital statusSingle1.48 [0.68–3.24]0.323NANA1.79 [0.76–4.22]0.181NANA2.54 [0.74–8.68]0.136NANA1.20 [0.47–3.04]0.707NANAMarried1.33 [0.57–3.08]0.506NANA1.36 [0.54–3.43]0.519NANA2.64 [0.74–9.48]0.136NANA0.42 [0.13–1.38]0.155NANACohabitation1.18 [0.48–2.89]0.723NANA1.34 [0.50–3.58]0.555NANA1.79 [0.45–7.07]0.406NANA0.73 [0.23–2.29]0.586NANAWidowed1.94 [0.63–6.01]0.248NANA2.61 [0.80–8.50]0.111NANA5.37 [1.22–23.65]0.0261.77 [0.62–5.04]0.2871.09 [0.25–4.77]0.907NANAGravidityNeverREFREFREFREFREFREFREFREFREFREFREFREFREFREFREF[1–5]0.93 [0.41–2.12]0.868NANA0.81 [0.35–1.86]0.621NANA1.12 [0.38–3.32]0.838NANA0.74 [0.27–2.03]0.562NANA[6–9]1.54 [0.63–3.74]0.314NANA1.13 [0.46–2.79]0.794NANA1.75 [0.55–5.57]0.343NANA0.74 [0.24–2.32]0.604NANA≥101.01 [0.31–3.32]0.985NANA1.01 [0.31–3.32]0.985NANA1.01 [0.21–4.90]0.991NANA0.78 [0.17–3.59]0.754NANAParityNeverREFREFNAREFREFREFREFREFREFREFREFREFREFREFREF[1–5]0.97 [0.54–1.73]0.917NANA0.87 [0.48–1.58]NANA0.74 [0.37–1.49]0.404NANA0.97 [0.45–2.10]0.945NANA[6–9]1.49 [0.68–3.24]0.316NANA1.33 [0.60–2.98]0.483NANA1.49 [0.61–3.65]0.386NANA0.83 [0.26–2.61]0.747NANA≥100.17 [0.00–589.21]0.986NANA0.03 [0.01–27.48]0.999NANA0.05 [0.001–54.25]0.999NANA0.05 [0.01–74.2]0.999NANANumber of lifetime sex partners1REFREFREFREFREFREFREFREFREFREFREFREFREFREFREF[2–5]2.27 [1.34–3.85]0.0021.63 [0.93–2.88]0.0882.10 [1.21–3.63]0.0081.51 [0.84–2.72]0.1661.59 [0.83–3.04]0.161NANA2.88 [1.40–5.94]<0.011.90 [0.96–3.76]0.065[6–9]2.45 [1.22–4.89]0.0111.69 [0.80–3.56]0.1682.23 [1.08–4.60]0.0291.53 [0.71–3.33]0.2791.38 [.55–3.45]0.491NANA3.41 [1.40–8.33]<0.012.43 [1.02–5.74]0.044≥106.45 [3.20–13.00]<0.00014.29 [2.00–9.20]<0.0014.92 [2.40–10.10]<0.00013.22 [1.46–7.08]<0.014.74 [2.16–10.39]<0.0012.95 [1.40–6.24]<0.012.16 [0.72–6.47]0.167NANAMenopause0.69 [0.42–1.13]0.1377NANA0.75 [0.45–1.25]0.523NANA0.84 [0.46–1.53]0.565NANA0.73 [0.37–1.45].372NANAVIA/VILI + 2.87 [1.62–5.06]<0.0012.91 [1.57–5.40]<0.0012.95 [1.65–5.28]<0.0012.92 [1.56–5.46]<0.0012.52 [1.29–4.91]<0.012.41 [1.19–4.88]0.0141.97 [0.93–4.18]0.076NANAHIV Status5.34 [3.13–9.09]<0.00013.89 [1.83–8.24]<0.0014.61 [2.68–7.92]<0.00013.18 [1.48–6.81]<0.013.74 [2.04–6.88]<0.00012.59 [1.11–6.07]0.0284.22 [2.22–8.02]<0.00012.95 [1.16–7.5]0.023Nota bene: Significant P values are presented in bold.aOR adjusted odds ratio, CI confidence interval, HIV Human immunodeficiency virus, HPV human papillomavirus, STI sexually transmitted infections, VIA Visual inspection with acetic acid, VILI Visual inspection with Lugol Iodine.a P values were calculated using Pearson χ2 or Fisher exact tests.b NA: Not applicable for variables with P values not significant in the univariate analysis.cREF: Reference categories.dNonavalent vaccine carcinogenic HPV (HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52, and HPV-58).eNon-vaccine carcinogenic HPV (HPV-35, HPV-39, HPV-51, HPV-56, HPV-59, HPV-68). Table 3Logistic regression analyses of risk factors of HPV outcomes in Gabonese women (n = 1524) living in Libreville during 2022-2024HPVAny carcinogenic HPVNonavalent carcinogenic HPVdNon-vaccine carcinogenic HPVecOR [95% CI]PaaOR [95% CI]PcOR [95% CI]PaOR [95% CI]PcOR [95% CI]PaOR [95% CI]PcOR [95% CI]PaOR [95% CI]PAge<30REFcREFREFREFREFREFREFREFREFREFREFREFREFREFREF[30–39]0.77 [0.42–10.43]0.414NAbNA0.69 [0.36–1.32]0.263NANA0.94 [0.43–2.04]0.875NANA0.40 [0.17–0.93]0.0330.76 [0.35–1.66]0.493[40–49]0.96 [0.53–1.73]0.884NANA0.84 [0.45–1.56]0.581NANA0.99 [0.46–2.14]0.987NANA0.54 [0.25–1.17]0.118NANA[50–59]0.93 [0.48–1.81]0.825NANA0.89 [0.45–1.78]0.741NANA10.17 [0.51–2.69]0.704NANA0.55 [0.23–1.34]0.191NANA≥600.58 [0.23–1.44]0.239NANA0.64 [0.25–1.60]0.339NANA0.87 [0.29–2.58]0.803NANA0.51 [0.16–1.59]0.245NANAOccupation statusEmployeeREFREFREFREFREFREFREFREFREFREFREFREFREFREFREFStudent2.90 [0.98–8.58]0.0501.85 [0.58–5.90]0.2973.74 [1.25–11.21]0.0182.31 [0.73–7.32]0.1531.07 [0.23–5.02]0.929NANA4.31 [1.22–15.25]0.0232.79 [0.81–9.65]0.105Retired1.42 [0.85–2.37]0.181NANA1.56 [0.48–5.05]0.457NANA3.22 [0.93–11.08]0.064NANA1.44 [0.30–6.87]0.651NANAHighest education levelNever schooled0.97 [0.37–2.57]0.953NANA0.98 [0.35–2.74]0.975NANA1.17 [0.35–3.88]0.798NANA1.05 [0.29–3.87]0.937NANAHigh school1.18 [0.60–2.29]0.633NANA1.25 [0.62–2.51]0.531NANA1.34 [0.58–3.12]0.491NANA1.12 [.45–2.77]0.806NANAUniversity0.72 [0.37–1.40]0.331NANA0.70 [0.35–1.43]0.333NANA0.75 [0.32–1.78]0.514NANA0.78 [0.31–1.95]0.596NANAMarital statusSingle1.48 [0.68–3.24]0.323NANA1.79 [0.76–4.22]0.181NANA2.54 [0.74–8.68]0.136NANA1.20 [0.47–3.04]0.707NANAMarried1.33 [0.57–3.08]0.506NANA1.36 [0.54–3.43]0.519NANA2.64 [0.74–9.48]0.136NANA0.42 [0.13–1.38]0.155NANACohabitation1.18 [0.48–2.89]0.723NANA1.34 [0.50–3.58]0.555NANA1.79 [0.45–7.07]0.406NANA0.73 [0.23–2.29]0.586NANAWidowed1.94 [0.63–6.01]0.248NANA2.61 [0.80–8.50]0.111NANA5.37 [1.22–23.65]0.0261.77 [0.62–5.04]0.2871.09 [0.25–4.77]0.907NANAGravidityNeverREFREFREFREFREFREFREFREFREFREFREFREFREFREFREF[1–5]0.93 [0.41–2.12]0.868NANA0.81 [0.35–1.86]0.621NANA1.12 [0.38–3.32]0.838NANA0.74 [0.27–2.03]0.562NANA[6–9]1.54 [0.63–3.74]0.314NANA1.13 [0.46–2.79]0.794NANA1.75 [0.55–5.57]0.343NANA0.74 [0.24–2.32]0.604NANA≥101.01 [0.31–3.32]0.985NANA1.01 [0.31–3.32]0.985NANA1.01 [0.21–4.90]0.991NANA0.78 [0.17–3.59]0.754NANAParityNeverREFREFNAREFREFREFREFREFREFREFREFREFREFREFREF[1–5]0.97 [0.54–1.73]0.917NANA0.87 [0.48–1.58]NANA0.74 [0.37–1.49]0.404NANA0.97 [0.45–2.10]0.945NANA[6–9]1.49 [0.68–3.24]0.316NANA1.33 [0.60–2.98]0.483NANA1.49 [0.61–3.65]0.386NANA0.83 [0.26–2.61]0.747NANA≥100.17 [0.00–589.21]0.986NANA0.03 [0.01–27.48]0.999NANA0.05 [0.001–54.25]0.999NANA0.05 [0.01–74.2]0.999NANANumber of lifetime sex partners1REFREFREFREFREFREFREFREFREFREFREFREFREFREFREF[2–5]2.27 [1.34–3.85]0.0021.63 [0.93–2.88]0.0882.10 [1.21–3.63]0.0081.51 [0.84–2.72]0.1661.59 [0.83–3.04]0.161NANA2.88 [1.40–5.94]<0.011.90 [0.96–3.76]0.065[6–9]2.45 [1.22–4.89]0.0111.69 [0.80–3.56]0.1682.23 [1.08–4.60]0.0291.53 [0.71–3.33]0.2791.38 [.55–3.45]0.491NANA3.41 [1.40–8.33]<0.012.43 [1.02–5.74]0.044≥106.45 [3.20–13.00]<0.00014.29 [2.00–9.20]<0.0014.92 [2.40–10.10]<0.00013.22 [1.46–7.08]<0.014.74 [2.16–10.39]<0.0012.95 [1.40–6.24]<0.012.16 [0.72–6.47]0.167NANAMenopause0.69 [0.42–1.13]0.1377NANA0.75 [0.45–1.25]0.523NANA0.84 [0.46–1.53]0.565NANA0.73 [0.37–1.45].372NANAVIA/VILI + 2.87 [1.62–5.06]<0.0012.91 [1.57–5.40]<0.0012.95 [1.65–5.28]<0.0012.92 [1.56–5.46]<0.0012.52 [1.29–4.91]<0.012.41 [1.19–4.88]0.0141.97 [0.93–4.18]0.076NANAHIV Status5.34 [3.13–9.09]<0.00013.89 [1.83–8.24]<0.0014.61 [2.68–7.92]<0.00013.18 [1.48–6.81]<0.013.74 [2.04–6.88]<0.00012.59 [1.11–6.07]0.0284.22 [2.22–8.02]<0.00012.95 [1.16–7.5]0.023Nota bene: Significant P values are presented in bold.aOR adjusted odds ratio, CI confidence interval, HIV Human immunodeficiency virus, HPV human papillomavirus, STI sexually transmitted infections, VIA Visual inspection with acetic acid, VILI Visual inspection with Lugol Iodine.a P values were calculated using Pearson χ2 or Fisher exact tests.b NA: Not applicable for variables with P values not significant in the univariate analysis.cREF: Reference categories.dNonavalent vaccine carcinogenic HPV (HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52, and HPV-58).eNon-vaccine carcinogenic HPV (HPV-35, HPV-39, HPV-51, HPV-56, HPV-59, HPV-68). Logistic regression analyses of risk factors of HPV outcomes in Gabonese women (n = 1524) living in Libreville during 2022-2024 Nota bene: Significant P values are presented in bold. aOR adjusted odds ratio, CI confidence interval, HIV Human immunodeficiency virus, HPV human papillomavirus, STI sexually transmitted infections, VIA Visual inspection with acetic acid, VILI Visual inspection with Lugol Iodine. a P values were calculated using Pearson χ2 or Fisher exact tests. b NA: Not applicable for variables with P values not significant in the univariate analysis. cREF: Reference categories. dNonavalent vaccine carcinogenic HPV (HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52, and HPV-58). eNon-vaccine carcinogenic HPV (HPV-35, HPV-39, HPV-51, HPV-56, HPV-59, HPV-68). Population attributable fractions of cervical abnormalities due to carcinogenic HPV infections and individual genotypes Of the 1524 women included in the study, 1429 (93.37%) underwent cervical abnormality screening using VIA/VILI. Overall, 128 (8.95%) participants exhibited VIA/VILI-detected abnormal cytological results. Adjusted population attributable fractions (PAFs) for VIA/VILI-detected abnormalities were estimated for (i) any carcinogenic HPV infection, (ii) nonavalent vaccine-targeted carcinogenic HPV only, (iii) non-vaccine carcinogenic HPV only, (iv) concurrent infection with both vaccine and non-vaccine carcinogenic HPV, and (v) individual HPV genotypes. Results are presented in Fig. 2B and Table 4. Overall, any carcinogenic HPV infection accounted for 18.0% (95% CI: 8.66–23.81; aOR: 2.14; p < 0.01) of VIA/VILI-positive cases. The largest contribution was from nonavalent vaccine-targeted carcinogenic HPV only (PAF: 14.1%, 95% CI: 10.60–17.64; aOR: 3.33; p < 0.0001), whereas non-vaccine carcinogenic HPV only contributed less (PAF: 4.6%, 95% CI: 0.35–8.84; aOR: 1.77; p = 0.115). Concurrent vaccine and non-vaccine carcinogenic HPV infections had negligible impact. At the genotype level, HPV-16 showed the highest and significant attributable fraction (PAF: 5.3%, 95% CI: 3.64–6.93; aOR: 3.60; p = 0.002), followed by HPV-45 (PAF: 3.3%, 95% CI: 1.72–4.85; aOR: 3.06; p = 0.025). HPV-52, HPV-68, and HPV-31 contributed modestly without statistical significance. Notably, HPV-11 showed a non-negligible PAF (3.2%, 95% CI: 2.98–3.35; aOR: 40.04; p = 0.002), though interpretation is limited by its non-oncogenic nature, small case numbers, and concurrent infections with carcinogenic HPV.Table 4Adjusted population attributable fractions (PAF) for VIA/VILI-positive cervical abnormalities by HPV exposure (n = 1429)Total Prevalence [n (%)]Cases exposed [n (%)]aOR [95% CI]PaPAF (%) [95% CI]HPV genotype combinationsAny carcinogenic HPV infections265 (18.54)38 (14.33)2.14 [1.35–3.42]<0.0118.0 [8.66–23.81]Gardasil-9® carcinogenic HPV onlyc122 (8.57)22 (18.03)3.33 [1.86–5.94]<0.000114.1 [10.60–17.64]Non-vaccine carcinogenic HPV onlyd97 (6.78)12 (12.37)1.77 [0.87–3.59]0.1154.6 [0.35–8.84]Concurrent vaccine/non–vaccine45 (3.14)4 (8.88)0.79 [0.23–2.73]0.713−0.8 [−5.25 to 3.75]Non-oncogenic HPV genotypesHPV-68 (0.59)0 (0.0)NANANAHPV-115 (0.34)4 (80.0)40.04 [4.09–391.78]0.0023.2 [2.98–.35]HPV-8128 (1.95)4 (14.28)1.56 [0.52–4.70]0.4311.2 [−1.14 to 3.47]Carcinogenic HPV genotypesHPV-1636 (2.51)9 (25.0)3.60 [1.61–8.07]0.0025.3 [3.64–6.93]HPV-1825 (1.74)2 (8.0)0.91 [0.21–4.04]0.906−0.2 [−2.79 to 2.48]HPV-3121 (1.46)4 (19.04)2.40 [0.77–7.49]0.1311.9 [0.36–3.43]HPV-3321 (1.46)3 (14.28)1.73 [0.49–6.10]0.3921.0 [−0.74 to 2.82]HPV-3550 (3.49)2 (4.0)0.36 [0.08–1.50]0.159−2.9 [−9.45 to 3.61]HPV-3918 (1.25)2 (11.11)1.07 [0.24–4.83]0.9290.1 [−2.18 to 2.39]HPV-4523 (1.61)6 (26.08)3.06 [1.14–8.16]0.0253.3 [1.72–4.85]HPV-5113 (0.9)2 (15.4)1.36 [0.28–6.51]0.7040.4 [−1.45 to 2.31]HPV-5245 (3.14)7 (15.55)1.86 [0.79–4.35]0.1492.6 [0.05–5.23]HPV-5641 (2.86)4 (9.75)0.98 [0.34-2.85]0.971−0.1 [−3.61 to 3.47]HPV-5830 (2.09)5 (16.66)2.06 [0.75–5.66]0.1592.1 [0.11–4.08]HPV-5919 (1.32)1 (5.26)0.63 [0.08–4.89]0.659−0.5 [−3.11 to 2.16]HPV-6827 (1.88)5 (18.51)2.01 [0.73–5.56]0.1792.0 [−0.02 to 4.11]Possibly carcinogenic HPV genotypesHPV-2615 (1.04)3 (20.0)2.17 [0.58–8.07]0.2491.3 [−0.16 to 2.79]HPV-5322 (1.53)3 (13.63)1.63 [0.46–5.76]0.4510.9 [−0.95 to 2.83]HPV-6614 (0.97)3 (21.43)2.58 [0.68–9.77]0.1631.5 [0.23–2.75]HPV-7311 (0.76)2 (18.18)2.50 [0.50–12.54]0.2631.0 [−0.07 to 2.02]HPV-8212 (0.84)2 (16.66)1.70 [0.35–8.12]0.5080.7 [−0.83 to 2.17]Nota bene: Significant P values are presented in bold.aP values were calculated using Pearson χ2 or Fisher exact tests.bNA: Not applicable as case exposed number is null.cPositive only for any of the following seven carcinogenic HPV (HPV-16, -18, -31, -33, -45, -52, and -58).dPositive only for any of the following six carcinogenic HPV (HPV-35, -39, -51, -56, -59, and -68).aOR adjusted odds ratio, CI confidence interval, HPV Human Papillomavirus, LR-HPV Low-risk HPV, PAF Population attributable fraction. Table 4Adjusted population attributable fractions (PAF) for VIA/VILI-positive cervical abnormalities by HPV exposure (n = 1429)Total Prevalence [n (%)]Cases exposed [n (%)]aOR [95% CI]PaPAF (%) [95% CI]HPV genotype combinationsAny carcinogenic HPV infections265 (18.54)38 (14.33)2.14 [1.35–3.42]<0.0118.0 [8.66–23.81]Gardasil-9® carcinogenic HPV onlyc122 (8.57)22 (18.03)3.33 [1.86–5.94]<0.000114.1 [10.60–17.64]Non-vaccine carcinogenic HPV onlyd97 (6.78)12 (12.37)1.77 [0.87–3.59]0.1154.6 [0.35–8.84]Concurrent vaccine/non–vaccine45 (3.14)4 (8.88)0.79 [0.23–2.73]0.713−0.8 [−5.25 to 3.75]Non-oncogenic HPV genotypesHPV-68 (0.59)0 (0.0)NANANAHPV-115 (0.34)4 (80.0)40.04 [4.09–391.78]0.0023.2 [2.98–.35]HPV-8128 (1.95)4 (14.28)1.56 [0.52–4.70]0.4311.2 [−1.14 to 3.47]Carcinogenic HPV genotypesHPV-1636 (2.51)9 (25.0)3.60 [1.61–8.07]0.0025.3 [3.64–6.93]HPV-1825 (1.74)2 (8.0)0.91 [0.21–4.04]0.906−0.2 [−2.79 to 2.48]HPV-3121 (1.46)4 (19.04)2.40 [0.77–7.49]0.1311.9 [0.36–3.43]HPV-3321 (1.46)3 (14.28)1.73 [0.49–6.10]0.3921.0 [−0.74 to 2.82]HPV-3550 (3.49)2 (4.0)0.36 [0.08–1.50]0.159−2.9 [−9.45 to 3.61]HPV-3918 (1.25)2 (11.11)1.07 [0.24–4.83]0.9290.1 [−2.18 to 2.39]HPV-4523 (1.61)6 (26.08)3.06 [1.14–8.16]0.0253.3 [1.72–4.85]HPV-5113 (0.9)2 (15.4)1.36 [0.28–6.51]0.7040.4 [−1.45 to 2.31]HPV-5245 (3.14)7 (15.55)1.86 [0.79–4.35]0.1492.6 [0.05–5.23]HPV-5641 (2.86)4 (9.75)0.98 [0.34-2.85]0.971−0.1 [−3.61 to 3.47]HPV-5830 (2.09)5 (16.66)2.06 [0.75–5.66]0.1592.1 [0.11–4.08]HPV-5919 (1.32)1 (5.26)0.63 [0.08–4.89]0.659−0.5 [−3.11 to 2.16]HPV-6827 (1.88)5 (18.51)2.01 [0.73–5.56]0.1792.0 [−0.02 to 4.11]Possibly carcinogenic HPV genotypesHPV-2615 (1.04)3 (20.0)2.17 [0.58–8.07]0.2491.3 [−0.16 to 2.79]HPV-5322 (1.53)3 (13.63)1.63 [0.46–5.76]0.4510.9 [−0.95 to 2.83]HPV-6614 (0.97)3 (21.43)2.58 [0.68–9.77]0.1631.5 [0.23–2.75]HPV-7311 (0.76)2 (18.18)2.50 [0.50–12.54]0.2631.0 [−0.07 to 2.02]HPV-8212 (0.84)2 (16.66)1.70 [0.35–8.12]0.5080.7 [−0.83 to 2.17]Nota bene: Significant P values are presented in bold.aP values were calculated using Pearson χ2 or Fisher exact tests.bNA: Not applicable as case exposed number is null.cPositive only for any of the following seven carcinogenic HPV (HPV-16, -18, -31, -33, -45, -52, and -58).dPositive only for any of the following six carcinogenic HPV (HPV-35, -39, -51, -56, -59, and -68).aOR adjusted odds ratio, CI confidence interval, HPV Human Papillomavirus, LR-HPV Low-risk HPV, PAF Population attributable fraction. Adjusted population attributable fractions (PAF) for VIA/VILI-positive cervical abnormalities by HPV exposure (n = 1429) Nota bene: Significant P values are presented in bold. aP values were calculated using Pearson χ2 or Fisher exact tests. bNA: Not applicable as case exposed number is null. cPositive only for any of the following seven carcinogenic HPV (HPV-16, -18, -31, -33, -45, -52, and -58). dPositive only for any of the following six carcinogenic HPV (HPV-35, -39, -51, -56, -59, and -68). aOR adjusted odds ratio, CI confidence interval, HPV Human Papillomavirus, LR-HPV Low-risk HPV, PAF Population attributable fraction. Discussion The overall prevalence of HPV infection (21.0%) and carcinogenic HPV types (18.5%) in our cohort was lower than in earlier Gabonese studies, which mostly included women referred for cervical cancer screening because of gynecological symptoms or with confirmed high-grade lesions and invasive cancer6,10–13,16,18, and therefore may have overestimated the population-level burden. Our estimates are consistent with WHO regional prevalence data (24%)3 and comparable findings from other Central African countries7–9,14, reinforcing the representativeness of our study and providing an updated baseline for genotype-specific surveillance in Gabon. The genotype-specific profile observed highlights the promising high coverage achievable with the nonavalent vaccine, while also indicating the continued circulation of non-vaccine carcinogenic types that may sustain residual disease risk. Indeed, nonavalent vaccine-targeted genotypes represented approximately 63% of all high-risk infections, with HPV-52 (3.1%), HPV-16 (2.5%), and HPV-58 (2.03%) emerging as the leading contributors. This pattern mirrors previous data reported in Gabon and from neighboring Central African countries, where HPV-16 and HPV-52 consistently ranked among the leading carcinogenic types6–18. Such profile supports the expected benefit of the implementation of the nonavalent vaccine in Gabon, which can typically prevent around 90% of HPV-associated cancers5, with no evidence to date of type replacement following elimination of vaccine-targeted genotypes23,24. Nonetheless, several non-vaccine carcinogenic types remained common in this population, particularly HPV-35 (3.6%), which was the most prevalent types. HPV-35 warrants particular attention, as it represents a substantial proportion of cervical cancers in SSA25, and is associated with higher mortality among Black women globally26. These disparities may reflect population-specific oncogenic determinants27,28 and justifying the inclusion of HPV-35 in next-generation vaccine currently under clinical evaluation29. Nevertheless, global evidence synthesized by Wei and colleagues shows that genotype-specific causal patterns in invasive cervical cancer remain remarkably consistent across regions5, supporting a rapid scale-up of Gardasil-9 rather than delaying vaccination in anticipation of expanded vaccine formulations. Taken together, these data indicate that the nonavalent vaccine is well matched to the dominant oncogenic burden in Gabon, and if implemented at scale, could prevent a substantial proportion of infections. However, organized HPV-based screening and surveillance remain essential to address prevalent non-vaccine carcinogenic types, particularly HPV-35. The genotype-specific PAF estimates further elucidate the relative contributions of circulating HPV types to cervical abnormalities in our study population, providing guidance for preventive intervention priorities. The greatest attributable burden was observed for nonavalent vaccine-targeted types (PAF: 14.1%), particularly HPV-16 (PAF: 5.3%) and HPV-45 (PAF: 3.3%), consistent with their well-established oncogenic dominance3,5,30. Although HPV35 was highly prevalent, it conferred no measurable excess risk. Although HPV-52 and HPV-58 are less oncogenic than HPV-16, their contributions, albeit modest, reinforce the added value of nonavalent vaccine coverage in that population. If vaccine-targeted infections are reduced through high vaccination coverage, the substantial proportion of VIA/VILI-detected abnormalities attributable to those types would be expected to decline, reinforcing the public-health value of nationwide implementation in Gabon. Although HPV-11 is non-oncogenic, its apparent association with VIA/VILI-detected abnormalities likely reflects co-infection with carcinogenic HPV types5. Carcinogenic HPV infections were independently associated with HIV positivity, multiple lifetime sexual partners and VIA/VILI positivity, consistent with established behavioral and immunological risk patterns31–33. These replicated associations support the robustness of our data and highlight the continued need for HPV-based screening and tailored triage among women living with HIV, who face elevated risk of disease progression32,33. Nonetheless, the cross-sectional design of the study precludes assessment of infection persistence or progression, and VIA/VILI, although practical for low-income settings, may underestimate lesion prevalence34. In line with WHO recommendations, HPV DNA testing is considered the preferred primary screening approach owing to its superior sensitivity and reproducibility35, however, implementation remains challenging in many sub-Saharan African settings due to infrastructural and cost constraints35. Furthermore, focusing genotyping on the eight WHO-recognized high-risk HPV types that are causally linked to cervical carcinogenesis4,5, within the test-triage-treat framework, would enhance specificity and clinical utility, whereas broader genotyping panels may reduce specificity and increase unnecessary follow-up without additional diagnostic benefit. Longitudinal follow-up with histopathological confirmation will be essential to assess genotype persistence and true disease risk overtime35. Nevertheless, these baseline findings strengthen the rationale for scaling up HPV molecular testing alongside vaccination, in line with the WHO cervical cancer elimination strategy36. Limitations include the cross-sectional design, which precludes causal inference; the potential for residual confounding despite adjustment; and the reliance on VIA/VILI as the measure of cervical abnormality, which has lower sensitivity than liquid-based cytology or histology. In addition, HPV detection was based on a single time point, which does not differentiate between transient and persistent infections. The relatively low prevalence of certain genotypes limited statistical power to detect associations. Missing data for several socio-demographic and behavioral variables (e.g., education, employment, sexual behavior, gravidity, parity) further restricted the completeness of risk factor assessment. Finally, the opportunistic nature of our screening may not fully represent the general female population of Gabon. Building on these observations, the public-health implications for Gabon are considerable. The predominance of nonavalent vaccine-targeted genotypes indicates that its introduction and the sustained high coverage could markedly reduce the burden of precancerous lesions and cervical cancers. Integrating vaccination into existing community initiatives such as the “Octobre Rose” campaigns offers an equitable and practical path to rapid implementation, while the recent WHO’s endorsement of a single-dose schedule will further enhance feasibility and cost-effectiveness, particularly if prioritised for adolescents before sexual debut22. Nonetheless, carcinogenic non-vaccine HPV types, particularly HPV-35, will persist, underscoring the importance of sustained screening and molecular surveillance. Collectively, this study establishes a reliable population-based baseline for HPV genotype distribution and attributable risk in Gabon, showing that most oncogenic infections and VIA/VILI-detected abnormalities are potentially preventable through nonavalent vaccine. Coordinating vaccination, HPV DNA testing, and longitudinal follow-up with more sensitive histopathological confirmation within reproductive-health services would provide a robust framework for cervical cancer prevention aligned with the WHO 2030 elimination strategy36 and contribute to equitable global progress toward ending cervical cancer as a public-health threat. Methods Study design and participants We conducted a 3-year descriptive cross-sectional study to investigate the distribution of carcinogenic HPV genotypes and associated determinants among adult women in Libreville, Gabon, during the 2022, 2023, and 2024 Octobre Rose cervical cancer screening campaigns. Each October, women aged ≥18 years attending participating clinics were offered free consultations, health education, and screening for genital HPV infection and cervical abnormalities using VIA/VILI staining methods. All participants included in this study were adult women (female sex assigned at birth), consistent with the biological focus on HPV infection of the cervix and cervical cancer risk, which affect only individuals with a cervix. Gender identity was not collected, as it was not relevant to the screening programme or the scientific objectives of this study. Consequently, sex- or gender-stratified analyses were not performed. Eligible participants were Gabonese residents of Libreville with a cervix who provided written informed consent. No financial compensation was provided, as screening was offered free of charge within the national cervical cancer prevention programme. Exclusion criteria were prior hysterectomy, current pregnancy, lactation, menstruation, or uninterpretable HPV genotyping results. Socio-demographic, economic, sexual, and reproductive health data were collected at enrolment using a standardised questionnaire. Before VIA/VILI screening, cervicovaginal samples were collected by trained gynaecologists using a cervical brush (Cervex-Brush; Hologic, Bedford, MA, USA) and preserved in liquid-based cytology medium (ThinPrep; Hologic). Samples were transported to the Virology Department, National Laboratory of Public Health, for HPV DNA detection and genotyping, and stored at -80 °C until analysis. HPV DNA extraction and genotyping Viral DNA from exfoliated cervical cells was extracted using the QIAamp Viral DNA Mini Kit (Qiagen, Hilden, Germany). HPV DNA was detected using the BioPerfectus HPV Real-Time PCR kit (BioPerfectus Technologies, Taizhou, Jiangsu, China), which detects 21 genotypes through amplification of conserved regions located within the L1, L2, or E1 genes, depending on the HPV type. The assay specifically identifies HPV-16 and HPV-18, while classifying other types as collectively HPV-positive. Then, positive samples were subsequently genotyped by amplifying a 100-base-pair fragment of the L1 gene using the BioPerfectus HPV Genotyping Multiplex Real-Time PCR assay. According to the International Agency for Research on Cancer (IARC) Working Group classification (IARC 2022), this method discriminates 13 genotypes considered as carcinogenic HPV, including HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, and -59 from Group 1 (carcinogenic to human) and HPV-68 from Group 2 A (probably carcinogenic to human). This assay can also distinguish additional five genotypes (HPV-26, -53, -66, -73, and -82) from Group 2B (possibly carcinogenic to human) and three non-oncogenic types (HPV-6, -11, and -81), as described previously37. Visual inspection with acetic acid and Lugol’s iodine VIA and VILI were performed according to WHO and IARC guidelines. For VIA, the cervix was examined after application of 5% acetic acid, with positivity defined as acetowhite lesions at the squamocolumnar junction. For VILI, Lugol’s iodine was applied, with mustard-yellow staining of the same area considered positive. Women testing positive by either method were classified as having cytological abnormalities and referred for colposcopy. Statistical analysis Anonymized participant characteristics and HPV results were entered into Excel and analysed using DATAtab version 1 (Graz, Austria; https://datatab.net). Quantitative variables were summarised as mean (±SD) or median (IQR), and categorical variables as proportions with 95% confidence intervals (CIs). Group comparisons used Pearson’s χ² or Fisher’s exact tests for categorical variables. A two-sided p < 0.05 was considered statistically significant. Prevalence estimates were calculated for overall HPV, carcinogenic HPV, nonavalent vaccine-targeted carcinogenic HPV, and non-vaccine carcinogenic HPV infections. Univariate and multivariate logistic regression models estimated crude odds ratios (cORs) and adjusted odds ratios (aORs) with 95% CIs. Variables with cOR and aOR >1 and p < 0.05 were considered significant risk factors. Adjusted population attributable fractions (PAFs) for VIA/VILI-positive abnormalities were estimated for (i) Any carcinogenic HPV infection, (ii) Gardasil-9® carcinogenic HPV only, (iii) Non-vaccine carcinogenic HPV only, and (iv) concurrent infection with both vaccine and non-vaccine carcinogenic HPV. Multivariable logistic regression models were fitted with VIA/VILI positivity as the dependent variable and mutually exclusive carcinogenic HPV exposure categories (reference: no carcinogenic HPV), adjusting for age, employment status, education, marital status, gravidity, parity, lifetime number of sexual partners, HIV status, and menopause. Adjusted PAFs were computed using the Bruzzi (Miettinen) method:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${{\rm{PAF}}}={\sum }_{{{\rm{k}}}}[{{{\rm{p}}}}_{{{\rm{k}}},{{\rm{cases}}}} \times ({{\rm{aO}}}{{{\rm{R}}}}_{{{\rm{k}}}}-1)/{{\rm{aO}}}{{{\rm{R}}}}_{{{\rm{k}}}}],$$\end{document}PAF=∑k[pk,cases×(aORk−1)/aORk],where pk,cases is the proportion of cases exposed in category k, and aORk is the adjusted odds ratio for category k versus the reference group. For individual HPV genotypes, PAFs were estimated in genotype-specific models (one at a time) using the same adjustment set. It is noted that the PAFs for individual HPV genotypes do not sum due to overlapping infections. These additional statistical analyses were conducted using R software v4.3.2. Ethic statement The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board and Ethics Committee of the Gabonese Ministry of Health and Social Affairs (protocol code: 00416/PR-MSPP, date of approval: April 2022). All women were aged 18 years and older and signed the written informed consent form of the study prior to enrollment. Data collection was done in accordance with Chapter 3, section 2, article 70, of Law No. 025/2023 of 09/07/2023 amending Law No. 001/2011 of 25 September 2011 on the protection of personal data. Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article. Supplementary information Peer Review file Reporting Summary Peer Review file Reporting Summary Source data Source Data Source Data